Caplyta Bipolar Mania: Second Phase 3 Win Sets Up J&J FDA Filing
J&J’s Caplyta (lumateperone) beat placebo in Study 452, its second pivotal Phase 3 trial in bipolar I mania, clearing the way for an FDA filing. Here is how the two studies compare.
Tag: bipolar I disorder
Read More